
Thomas O Krag

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2074494/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Growth Factors Do Not Improve Muscle Function in Young or Adult mdx Mice. Biomedicines, 2022, 10, 304.	1.4	0
2	Preclinical Research in McArdle Disease: A Review of Research Models and Therapeutic Strategies. Genes, 2022, 13, 74.	1.0	4
3	Three novel <i>FHL1</i> variants cause a mild phenotype of Emeryâ€Dreifuss muscular dystrophy. Human Mutation, 2022, 43, 1234-1238.	1.1	2
4	Approaches for Systemic Delivery of Dystrophin Antisense Peptide Nucleic Acid in the mdx Mouse Model. Nucleic Acid Therapeutics, 2021, 31, 208-219.	2.0	7
5	251st ENMC international workshop: Polyglucosan storage myopathies 13–15 December 2019, Hoofddorp, the Netherlands. Neuromuscular Disorders, 2021, 31, 466-477.	0.3	4
6	Antimyostatin Treatment in Health and Disease: The Story of Great Expectations and Limited Success. Cells, 2021, 10, 533.	1.8	19
7	No effect of resveratrol in patients with mitochondrial myopathy: A crossâ€over randomized controlled trial. Journal of Inherited Metabolic Disease, 2021, 44, 1186-1198.	1.7	4
8	Autophagy is affected in patients with hypokalemic periodic paralysis: an involvement in vacuolar myopathy?. Acta Neuropathologica Communications, 2021, 9, 109.	2.4	2
9	Myopathy can be a key phenotype of membrin (GOSR2) deficiency. Human Mutation, 2021, 42, 1101-1106.	1.1	3
10	Novel Homozygous Truncating Variant Widens the Spectrum of Early-Onset Multisystemic SYNE1 Ataxia. Cerebellum, 2021, , 1.	1.4	0
11	Nampt controls skeletal muscle development by maintaining Ca2+ homeostasis and mitochondrial integrity. Molecular Metabolism, 2021, 53, 101271.	3.0	27
12	Muscle biopsy and <scp>MRI</scp> findings in <scp>ANO5</scp> â€related myopathy. Muscle and Nerve, 2021, 64, 743-748.	1.0	6
13	Extreme Hypoxia Causing Brady-Arrythmias During Apnea in Elite Breath-Hold Divers. Frontiers in Physiology, 2021, 12, 712573.	1.3	2
14	Growth and differentiation factor 15 as a biomarker for mitochondrial myopathy. Mitochondrion, 2020, 50, 35-41.	1.6	38
15	Vacuoles, Often Containing Glycogen, Are a Consistent Finding in Hypokalemic Periodic Paralysis. Journal of Neuropathology and Experimental Neurology, 2020, 79, 1127-1129.	0.9	2
16	MYASTHENIA & amp; RELATED DISORDERS. Neuromuscular Disorders, 2020, 30, S58.	0.3	0
17	MUSCLE FUNCTION & amp; HOMEOSTASIS / MOLECULAR THERAPEUTIC APPROACHES. Neuromuscular Disorders, 2020, 30, S68.	0.3	0
18	LIMB GIRDLE MUSCULAR DYSTROPHIES. Neuromuscular Disorders, 2020, 30, S90.	0.3	0

#	Article	IF	CITATIONS
19	Preserved Capacity for Adaptations in Strength and Muscle Regulatory Factors in Elderly in Response to Resistance Exercise Training and Deconditioning. Journal of Clinical Medicine, 2020, 9, 2188.	1.0	10
20	No effect of oral sucrose or IV glucose during exercise in phosphorylase b kinase deficiency. Neuromuscular Disorders, 2020, 30, 340-345.	0.3	4
21	Preclinical Research in Glycogen Storage Diseases: A Comprehensive Review of Current Animal Models. International Journal of Molecular Sciences, 2020, 21, 9621.	1.8	13
22	Results of an open label feasibility study of sodium valproate in people with McArdle disease. Neuromuscular Disorders, 2020, 30, 734-741.	0.3	3
23	A single c.1715G>C calpain 3 gene variant causes dominant calpainopathy with loss of calpain 3 expression and activity. Human Mutation, 2020, 41, 1507-1513.	1.1	15
24	Depletion of ATP Limits Membrane Excitability of Skeletal Muscle by Increasing Both ClC1-Open Probability and Membrane Conductance. Frontiers in Neurology, 2020, 11, 541.	1.1	9
25	Effect of Aerobic Exercise Training and Deconditioning on Oxidative Capacity and Muscle Mitochondrial Enzyme Machinery in Young and Elderly Individuals. Journal of Clinical Medicine, 2020, 9, 3113.	1.0	16
26	O.14B3GNT4 deficiency: a new α-dystroglycanopathy causing late-onset progressive brain atrophy and muscular dystrophy. Neuromuscular Disorders, 2019, 29, S118-S119.	0.3	0
27	<i>POPDC3</i> Gene Variants Associate with a New Form of Limb Girdle Muscular Dystrophy. Annals of Neurology, 2019, 86, 832-843.	2.8	27
28	P.119Analysis of the structural and metabolic consequences of McArdle disease using the murine model. Neuromuscular Disorders, 2019, 29, S83.	0.3	0
29	Deep morphological analysis of muscle biopsies from type III glycogenesis (GSDIII), debranching enzyme deficiency, revealed stereotyped vacuolar myopathy and autophagy impairment. Acta Neuropathologica Communications, 2019, 7, 167.	2.4	17
30	Palbociclib in combination with simvastatin induce severe rhabdomyolysis: a case report. BMC Neurology, 2019, 19, 247.	0.8	13
31	Low survival rate and muscle fiber-dependent aging effects in the McArdle disease mouse model. Scientific Reports, 2019, 9, 5116.	1.6	11
32	Adaptations in Mitochondrial Enzymatic Activity Occurs Independent of Genomic Dosage in Response to Aerobic Exercise Training and Deconditioning in Human Skeletal Muscle. Cells, 2019, 8, 237.	1.8	20
33	IL-6 release from muscles during exercise is stimulated by lactate-dependent protease activity. American Journal of Physiology - Endocrinology and Metabolism, 2019, 316, E940-E947.	1.8	48
34	Absence of p.R50X Pygm read-through in McArdle disease cellular models. DMM Disease Models and Mechanisms, 2019, 13, .	1.2	4
35	Expanding the phenotype of filamin-C-related myofibrillar myopathy. Clinical Neurology and Neurosurgery, 2019, 176, 30-33.	0.6	8
36	Collagen XII myopathy with rectus femoris atrophy and collagen XII retention in fibroblasts. Muscle and Nerve, 2018, 57, 1026-1030.	1.0	11

#	Article	IF	CITATIONS
37	Limb girdle muscular dystrophy due to mutations in <i>POMT2</i> . Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 506-512.	0.9	21
38	Exercising with blocked muscle glycogenolysis: Adaptation in the McArdle mouse. Molecular Genetics and Metabolism, 2018, 123, 21-27.	0.5	5
39	DMD TREATMENT: ANIMAL MODELS. Neuromuscular Disorders, 2018, 28, S96.	0.3	Ο
40	BAG3 myopathy is not always associated with cardiomyopathy. Neuromuscular Disorders, 2018, 28, 798-801.	0.3	11
41	Glycogen Synthesis in Glycogenin 1–Deficient Patients: A Role for Glycogenin 2 in Muscle. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 2690-2700.	1.8	16
42	Clinical heterogeneity and phenotype/genotype findings in 5 families with <i>GYG1</i> deficiency. Neurology: Genetics, 2017, 3, e208.	0.9	12
43	New advances in McArdle disease: Characterization of the p.R50X knock-in mouse model and evaluation of new therapeutic approaches. Neuromuscular Disorders, 2016, 26, S199.	0.3	Ο
44	Muscle involvement in limb-girdle muscular dystrophy with GMPPB deficiency (LGMD2T). Neurology: Genetics, 2016, 2, e112.	0.9	29
45	Differential Muscle Involvement in Mice and Humans Affected by McArdle Disease. Journal of Neuropathology and Experimental Neurology, 2016, 75, 441-454.	0.9	24
46	Differential glucose metabolism in mice and humans affected by McArdle disease. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2016, 311, R307-R314.	0.9	11
47	A New Mouse Model of Limb-Girdle Muscular Dystrophy Type 2I Homozygous for the Common L276I Mutation Mimicking the Mild Phenotype in Humans. Journal of Neuropathology and Experimental Neurology, 2015, 74, 1137-1146.	0.9	3
48	A New Mouse Model of Limb-Girdle Muscular Dystrophy Type 2I Homozygous for the Common L276I Mutation Mimicking the Mild Phenotype in Humans. Journal of Neuropathology and Experimental Neurology, 2015, 74, 1137-1146.	0.9	18
49	Molecular, morphological and physiological studies in a mouse model of McArdle disease: Similarities to the human disease. Neuromuscular Disorders, 2015, 25, S219.	0.3	0
50	Electroporation Enhanced Effect of Dystrophin Splice Switching PNA Oligomers in Normal and Dystrophic Muscle. Molecular Therapy - Nucleic Acids, 2015, 4, e267.	2.3	10
51	Effect of treatment with grow factors on muscle pathology in the mdx mouse model of Duchenne muscular dystrophy. Neuromuscular Disorders, 2015, 25, S291.	0.3	0
52	Protein-carbohydrate supplements improve muscle protein balance in muscular dystrophy patients after endurance exercise: a placebo-controlled crossover study. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2015, 308, R123-R130.	0.9	15
53	Muscle Atrophy Reversed by Growth Factor Activation of Satellite Cells in a Mouse Muscle Atrophy Model. PLoS ONE, 2014, 9, e100594.	1.1	22
54	A pilot study of muscle plasma protein changes after exercise. Muscle and Nerve, 2014, 49, 261-266.	1.0	15

#	Article	IF	CITATIONS
55	Effect of sildenafil on skeletal and cardiac muscle in <scp>B</scp> ecker muscular dystrophy. Annals of Neurology, 2014, 76, 550-557.	2.8	39
56	A novel de novo mutation of the mitochondrial tRNAlys gene mt.8340G>A associated with pure myopathy. Neuromuscular Disorders, 2014, 24, 162-166.	0.3	13
57	Anoctamin 5 muscular dystrophy in Denmark: prevalence, genotypes, phenotypes, cardiac findings, and muscle protein expression. Journal of Neurology, 2013, 260, 2084-2093.	1.8	63
58	Muscle biopsies off-set normal cellular signaling in surrounding musculature. Neuromuscular Disorders, 2013, 23, 981-985.	0.3	1
59	Muscle regeneration and inflammation in patients with facioscapulohumeral muscular dystrophy. Acta Neurologica Scandinavica, 2013, 128, 194-201.	1.0	15
60	Resistance training in patients with limbâ€girdle and becker muscular dystrophies. Muscle and Nerve, 2013, 47, 163-169.	1.0	43
61	P.8.12 Mild phenotype in a Limb Girdle muscular dystrophy type 2I mouse model homozygous for the common L276I mutation. Neuromuscular Disorders, 2013, 23, 783.	0.3	Ο
62	A new mutation of the fukutin gene causing late-onset limb girdle muscular dystrophy. Neuromuscular Disorders, 2013, 23, 562-567.	0.3	7
63	Muscle regeneration in mitochondrial myopathies. Mitochondrion, 2013, 13, 63-70.	1.6	6
64	Protein Turnover and Cellular Stress in Mildly and Severely Affected Muscles from Patients with Limb Girdle Muscular Dystrophy Type 2I. PLoS ONE, 2013, 8, e66929.	1.1	7
65	A possible role of MAP-1 in skeletal muscle regeneration. Immunobiology, 2012, 217, 1130.	0.8	Ο
66	Calpain 3 is important for muscle regeneration: Evidence from patients with limb girdle muscular dystrophies. BMC Musculoskeletal Disorders, 2012, 13, 43.	0.8	49
67	G.P.42 Protein turnover and cellular stress in mildly and severely affected muscles from patients with limb girdle muscular dystrophy type 2I. Neuromuscular Disorders, 2012, 22, 832.	0.3	Ο
68	T.P.36 Hepatocyte growth factor reverses atrophy by inducing protein synthesis in mice. Neuromuscular Disorders, 2012, 22, 863.	0.3	0
69	Level of muscle regeneration in limb-girdle muscular dystrophy type 2I relates to genotype and clinical severity. Skeletal Muscle, 2011, 1, 31.	1.9	26
70	Short―and longâ€ŧerm effects of endurance training in patients with mitochondrial myopathy. European Journal of Neurology, 2009, 16, 1336-1339.	1.7	44
71	No muscle involvement in myoclonusâ€dystonia caused by É›â€sarcoglycan gene mutations. European Journal of Neurology, 2008, 15, 525-529.	1.7	17
72	Phenotype and clinical course in a family with a new de novo Twinkle gene mutation. Neuromuscular Disorders, 2008, 18, 306-309.	0.3	13

#	Article	IF	CITATIONS
73	Endurance training improves fitness and strength in patients with Becker muscular dystrophy. Brain, 2008, 131, 2824-2831.	3.7	100
74	Endurance training: An effective and safe treatment for patients with LGMD2I. Neurology, 2007, 68, 59-61.	1.5	79
75	Heregulinâ€induced epigenetic regulation of the utrophinâ€A promoter. FEBS Letters, 2007, 581, 4153-4158.	1.3	15
76	Deletion of exon 16 of the dystrophin gene is not associated with disease. Human Mutation, 2007, 28, 205-205.	1.1	29
77	Aerobic training is safe and improves exercise capacity in patients with mitochondrial myopathy. Brain, 2006, 129, 3402-3412.	3.7	184
78	Myostatin propeptideâ€mediated amelioration of dystrophic pathophysiology. FASEB Journal, 2005, 19, 543-549.	0.2	219
79	Heregulin ameliorates the dystrophic phenotype in mdx mice. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 13856-13860.	3.3	112
80	Therapeutics for Duchenne muscular dystrophy: current approaches and future directions. Journal of Molecular Medicine, 2004, 82, 102-115.	1.7	91
81	Sp1 and the ets-related transcription factor complex GABPÎ \pm /Î ² functionally cooperate to activate the utrophin promoter. Journal of the Neurological Sciences, 2002, 197, 27-35.	0.3	23
82	Functional improvement of dystrophic muscle by myostatin blockade. Nature, 2002, 420, 418-421.	13.7	748
83	Harnessing the potential of dystrophin-related proteins for ameliorating Duchenne's muscular dystrophy. Acta Physiologica Scandinavica, 2001, 171, 349-358.	2.3	20
84	Identification of genes that are differentially expressed in extraocular and limb muscle. Journal of the Neurological Sciences, 2000, 179, 76-84.	0.3	15
85	Activation of Utrophin Promoter by Heregulin via the <i>ets</i> -related Transcription Factor Complex GA-binding Protein α/β. Molecular Biology of the Cell, 1999, 10, 2075-2086.	0.9	104
86	90-kDa Ribosomal S6 Kinase Is Phosphorylated and Activated by 3-Phosphoinositide-dependent Protein Kinase-1. Journal of Biological Chemistry, 1999, 274, 27168-27176.	1.6	220
87	Characterization of a glutathione S-transferase and a related glutathione-binding protein from gill of the blue mussel, Mytilus edulis. Biochemical Journal, 1995, 305, 145-150.	1.7	72